Treatment for Patients with UTI Symptoms but Normal Urinalysis

Understanding the Diagnostic Challenge

A normal urinalysis has excellent negative predictive value for ruling out UTI in patients with functioning bone marrow, but clinical symptoms may still indicate infection despite normal laboratory findings 1
Urinalysis has limited diagnostic accuracy in patients presenting with typical UTI symptoms, leading to only a minimal increase in diagnostic certainty 2
In cases where diagnosis is unclear but symptoms strongly suggest UTI, treatment decisions should prioritize clinical presentation over laboratory findings 2

The American Urological Association recommends nitrofurantoin (100 mg twice daily for 5 days) as the preferred first-line agent due to low resistance rates and rapid decay of resistance if present 3
Fosfomycin trometamol (3 g single dose) is an excellent alternative first-line option, particularly effective for uncomplicated cystitis, with convenient single-dose administration 2
Trimethoprim-sulfamethoxazole (160/800 mg twice daily for 3 days) can be used as a second-line option if local resistance rates are less than 20% 2
Cephalexin (500 mg twice daily for 3 days) can be used as a second-line option if E. coli resistance is less than 20% locally 2

For postmenopausal women, vaginal estrogen therapy can be considered in addition to antibiotics to reduce the risk of future UTIs, as it helps restore normal vaginal flora and urethral environment 4, 3
For patients with recurrent UTIs, urine culture should be obtained before starting treatment, and self-start antibiotic therapy can be considered for reliable patients who can obtain specimens before initiating treatment 3
For persistent symptoms, repeat urine culture should be performed to assess for ongoing bacteriuria before prescribing additional antibiotics, and evaluation for other causes of urinary symptoms should be considered if cultures remain negative 3, 4

Fluoroquinolones should be avoided for empiric treatment due to increasing resistance rates, FDA warning about unfavorable risk-benefit ratio for uncomplicated UTIs, and greater potential for collateral damage to gut microbiota 5
Treating asymptomatic bacteriuria in patients with recurrent UTIs should be avoided, as it fosters antimicrobial resistance and may increase the number of recurrent UTI episodes 3
Duration of therapy should be appropriate to the clinical scenario, with 3-5 days for uncomplicated cystitis and 7-14 days for complicated UTIs or pyelonephritis 2, 6